I think that the government has tried to craft certain things with the intention of trying to exclude some of that, although I know that you raised some concerns on some of the changes to the trademark definitions around distinctiveness. I think there are legitimate concerns on that.
I haven't been able to track claims that there are large numbers of cases that would bear out this change. I don't think that's the case.
My concern, particularly for generics and the distribution of generics, comes out of the in-transit issue. This is not speculation. In fact, I would argue it's not even unintended consequence. We know, based on the experience in other jurisdictions where you have the ability to target in-transit shipments, generic goods may well be swept up in that and the ability to see them shipped to the patients and people who need them most may be impeded.